Tirzepatide vs Retatrutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Mounjaro, Zepbound
Tirzepatide is a single peptide that activates two receptors at once: GIP and GLP-1, the two main incretin hormones your gut releases after eating. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. Like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound.
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In phase 2 it produced about 24 percent weight loss at the top dose, and in the phase 3 TRIUMPH-1 trial Lilly reported 28.3 percent at 12 mg over 80 weeks. It is investigational, made by Eli Lilly, and not FDA approved; Lilly plans to file with the FDA in the first quarter of 2027. Because it is not an approved drug, FDA says it cannot be legally compounded.
Key Comparison Insights
- Tirzepatide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Tirzepatide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
- Both are GLP-1 class medications compared in weight management studies.
Detailed Comparison
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tirzepatide is a dual agonist, meaning it switches on both the GIP receptor and the GLP-1 receptor with one molecule. GLP-1 activation boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite through the brain. Adding GIP activation appears to enhance insulin response and improve how fat tissue handles energy, and the combination seems to outperform hitting GLP-1 alone. As with semaglutide, the peptide carries a fatty-acid chain that binds albumin to extend its half-life enough for once-weekly dosing. The exact reason the GIP arm adds so much benefit is still being worked out, but the clinical effect of combining the two is clear. | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. |
| Common Dosing | 5-15 mg weekly (after titration) Once weekly | 4-12 mg weekly Once weekly, same day each week |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Morning, same day each week | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The trial evidence is strong and recent. In SURMOUNT-1 (New England Journal of Medicine, 2022), adults with obesity but without diabetes lost an average of 22.5% of body weight on the 15 mg dose over 72 weeks, versus 2.4% on placebo, with about 9 in 10 participants losing weight. In a head-to-head trial, SURMOUNT-5 (2025), tirzepatide produced roughly 20% weight loss versus about 14% for semaglutide. The SURPASS diabetes program showed strong HbA1c reductions, and a large cardiovascular outcomes trial supported its safety profile. Side effects mirror other incretin drugs: mostly nausea, diarrhea, and other gastrointestinal issues, generally worst during dose titration. These are large, randomized, peer-reviewed trials, putting tirzepatide among the best-evidenced metabolic drugs available. | The first big human evidence was the phase 2 trial by Jastreboff and colleagues (New England Journal of Medicine, 2023), which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48. In a liver-fat substudy of 98 participants, liver fat dropped by about 81 to 82 percent at the 8 and 12 mg doses by week 24. Phase 3 has since read out: in TRIUMPH-1, Lilly reported mean weight loss of 19.0, 25.9 and 28.3 percent at 4, 9 and 12 mg over 80 weeks versus 2.2 percent on placebo (efficacy estimand, which assumes people stayed on the drug; analyses counting everyone randomized come out a few points lower). TRIUMPH-2 (type 2 diabetes plus obesity) reached about 20.8 percent at 12 mg, and TRIUMPH-3 (severe obesity plus heart disease) about 22.6 percent. Side effects were dominated by dose-dependent gastrointestinal issues like nausea, vomiting, and diarrhea, plus a dysesthesia (skin sensitivity) signal at the top dose. Retatrutide sold outside of trials is not an approved, quality-controlled medicine. |
Frequently Asked Questions: Tirzepatide vs Retatrutide
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide is a weight loss peptide that tirzepatide is a single peptide that activates two receptors at once: gip and glp-1, the two main incretin hormones your gut releases after eating. it is fda-approved as mounjaro for type 2 diabetes and as zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound. Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in phase 2 it produced about 24 percent weight loss at the top dose, and in the phase 3 triumph-1 trial lilly reported 28.3 percent at 12 mg over 80 weeks. it is investigational, made by eli lilly, and not fda approved; lilly plans to file with the fda in the first quarter of 2027. because it is not an approved drug, fda says it cannot be legally compounded. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tirzepatide or Retatrutide?
Neither is universally "better" - the choice depends on your specific goals. Tirzepatide is typically used for weight loss purposes, while Retatrutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tirzepatide and Retatrutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tirzepatide and Retatrutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.